This statistic displays the rate of deaths caused by cardiovascular diseases in the United Kingdom from 2000 to 2022. In 2022, there were 264 deaths per 100,000 population from cardiovascular diseases, one of the lowest rates in the provided time interval.

This statistic displays the mortality rate from coronary heart disease in the United Kingdom in 2022, by country. In that year, Scotland had the highest death rate from the disease, with 129 deaths per 100,000 population.

Directly standardised mortality rate from cardiovascular disease for people aged under 75, per 100,000 population. To ensure that the NHS is held to account for doing all that it can to prevent deaths from cardiovascular disease in people under 75. Legacy unique identifier: P01730

This statistic shows the number of excess winter deaths caused by an underlying circulatory disease in England and Wales in 2020/21 and 2021/22, by age. In the winter period 2020/21, approximately 1.2 thousand individuals aged 90 years and over died from an underlying circulatory disease.

Update 2 March 2023: Following the merger of NHS Digital and NHS England on 1st February 2023 we are reviewing the future presentation of the NHS Outcomes Framework indicators. As part of this review, the annual publication which was due to be released in March 2023 has been delayed. Further announcements about this dataset will be made on this page in due course. Directly standardised mortality rate from cardiovascular disease for people aged under 75, per 100,000 population. To ensure that the NHS is held to account for doing all that it can to prevent deaths from cardiovascular disease in people under 75. Some different patterns have been observed in the 2020 mortality data which are likely to have been impacted by the coronavirus (COVID-19) pandemic. Statistics from this period should also be interpreted with care. Legacy unique identifier: P01730

This report provides provisional England, Clinical Commissioning Group (CCG) and GP practice level data for January to June 2021 (part of the NDA 2021-22 audit period). The worksheets include data for all CCGs and GP practices in England within the August 2021 extraction of NDA data (January 2021 to June 2021 data). These data are provisional and have been subject to fewer data quality and validation checks than data included in final NDA publications. Data for Local Health Boards (LHB) in Wales and Specialist Diabetes Services are not included in this publication. Their 2021-22 data (for the full audit period January 2021 to March 2022) will be extracted as part of the final NDA 2021-22 collection and reported in the NDA 2021-22 short report publication, scheduled for late 2022. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available. Please note that an issue has been identified with the source data from one GP system supplier whereby no records were submitted for a set of SNOMED codes relating to statin prescriptions, which are new for this audit period. This has resulted in the reported numerator counts, and associated percentages, for the completion of the following treatment targets being considerably lower than what is believed to be the true value: Primary Prevention - On Statins without CVD History, Secondary Prevention - On Statins with CVD History, Combined Prevention - On Statins, and All Three Treatment Targets NEW

In 2018, NHS England introduced a new Artificial Intelligence (AI) decision support technology into the health system in order to improve the diagnostic pathway of patients who were being investigated for suspected coronary artery disease.

The primary aim of the FISH and CHIPS study was to assess the impact of this health intervention by determining the differences in health-related events of a stable chest pain population undergoing Coronary Computed Tomography Angiography (CCTA) and Fractional Flow Reserve (FFR-CT), compared to a previous ‘standard of care’ diagnostic chest pain pathway of CCTA and non-invasive functional testing.

This is a multi-centre, retrospective, observational analytic cohort study design. The study utilised the electronic health record (EHR) data already collected by NHS England on all patients that underwent a CCTA for the assessment of coronary artery disease over a 3-year period (April 2017-April 2020). All patients were treated in accordance with the latest NICE clinical guidance (CG 95 2016). Healthcare data was used to determine clinical outcomes (heart attacks, death, cardiac death), procedures performed (invasive angiography, percutaneous stenting and surgical bypass grafting) and heart diagnostic tests up to 24 months following the index CCTA. Costs are determined from the NHS national tariff system.

Beneficial effects of therapeutic drugs are controversial for heart failure with preserved ejection fraction (HFpEF). This meta-analysis aimed to evaluate and compare the interactive effects of different therapeutic drugs and placebo in patients with HFpEF. A comprehensive search was conducted using PubMed, Google Scholar, and Cochrane Central Register to identify related articles published before March 2021. The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, heart failure (HF) hospitalization, and worsening HF events. A total of 14 randomized controlled trials, comprising 19,573 patients (intervention group, n = 9,954; control group, n = 9,619) were included in this network meta-analysis. All-cause mortality, cardiovascular mortality, and worsening HF events among therapeutic drugs and placebo with follow-up of 0.5–4 years were not found to be significantly correlated. The angiotensin receptor neprilysin inhibitor (ARNI) and angiotensin-converting enzyme inhibitor (ACEI) significantly reduced the HF hospitalizations compared with placebo (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.60–0.87 and HR 0.64, 95% CI 0.43–0.96, respectively), without heterogeneity among studies. The ARNI was superior to angiotensin receptor blocker (ARB) in reducing HF hospitalizations (HR 0.80, 95% CI 0.71–0.91), and vericiguat 10 mg ranked worse than beta-blockers for reducing all-cause mortality in patients with HFpEF (HR 3.76, 95% CI 1.06–13.32). No therapeutic drugs can significantly reduce mortality, but the ARNI or ACEI is associated with the low risk of HF hospitalizations for patients with HFpEF.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, identifier CRD42021247034

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

Excess Under 75 Mortality Rates in Adults With Serious Mental Illness, Excess under 75 mortality rates in adults with serious mental illness - 2019 to 2021 This indicator is a measure of the extent to which adults with a serious mental illness (SMI) die younger than adults without a serious mental illness (nSMI). To measure premature mortality in adults diagnosed with a serious mental illness (SMI).

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020. This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

Snapshot img

Cardiovascular Medical Devices Market Size 2024-2028

The cardiovascular medical devices market size is forecast to increase by USD 19.08 billion at a CAGR of 7.2% between 2023 and 2028.

The market is witnessing significant growth due to the increasing prevalence of cardiac conditions such as atrial fibrillation and clogged arteries. This trend is driven by the rising number of individuals with these conditions and the growth of insurance providers covering diagnostic monitoring devices. companies in this market are focusing on innovative technologies like Al and machine learning based electrocardiogram (ECG) technology to improve the accuracy and efficiency of cardiovascular diagnosis. Surgical devices, including ECG, Holter monitors, event monitors, and implantable loop recorders, are essential tools for the early detection and treatment of cardiovascular diseases. However, the high cost of cardiovascular procedures remains a challenge for market growth. To stay competitive, companies must offer cost-effective solutions while maintaining the highest standards of quality and patient safety. This market analysis report provides a comprehensive overview of the market growth factors, business strategies, and challenges shaping the future of the cardiovascular medical devices industry.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market holds significant importance in the healthcare industry as these devices play a crucial role in diagnosing, monitoring, and treating various heart disorders. Heart diseases, including heart failure, cardiomyopathy, and stroke, are fatal conditions that pose a major health concern worldwide. According to the World Health Organization (WHO), cardiovascular diseases accounted for approximately 17.9 million deaths in 2016. Minimally invasive procedures and advanced cardiovascular devices have revolutionized the treatment landscape, offering improved patient outcomes and reduced healthcare resources. Diagnostic monitoring devices, such as ECG and Holter monitors, enable early detection and timely intervention, thereby reducing the risk of complications and mortality.
In addition, cardiology devices, including coronary artery stents and surgical devices, have significantly contributed to the advancement of cardiovascular care. For instance, coronary artery stents help in the treatment of coronary artery diseases by improving blood flow and reducing the risk of heart attacks. Artificial intelligence (AI) is increasingly being integrated into cardiovascular devices to enhance their functionality and accuracy. AL-based ECG technology, for example, can analyze ECG data more efficiently and accurately than traditional methods, enabling early detection and diagnosis of heart conditions. The cardiovascular devices market is expected to witness steady growth due to the increasing prevalence of heart disorders and the need for advanced diagnostic and therapeutic solutions.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Diagnostic and monitoring systems
  Surgical devices


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Product Insights

The diagnostic and monitoring systems segment is estimated to witness significant growth during the forecast period.

The diagnostic and monitoring segment of the international market comprises various devices that play a vital role in evaluating heart health, identifying cardiovascular diseases (CVDs) in their initial stages, and tracking disease progression or treatment response. This segment includes devices like ECGs, which measure the electrical activity of the heart and are crucial for diagnosing arrhythmias, heart attacks, and other cardiac conditions. Furthermore, echocardiograms, which employ ultrasound technology to generate detailed images of the heart, aid in assessing structural heart diseases and evaluating heart function. Portable ECG devices, such as Holter monitors and event monitors, are also part of this segment. These devices enable continuous heart monitoring over extended durations, allowing doctors to detect irregularities that may not surface during routine ECG tests.

Get a glance at the market report of share of various segments Request Free Sample

The diagnostic and monitoring systems segment was valued at USD 21.14 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 38% to the growth of the global market during the fore

Objectives: A systematic review and meta-analysis was performed to evaluate the potential prognostic role of serum uric acid (SUA) in patients with chronic heart failure (CHF).Methods: The Embase, PubMed, Web of Science and Cochrane Library databases were searched up to 5 April 2021 for relevant publications. Random effects model was used to pool data. STATA15.0 software was used to perform meta-analysis. Heterogeneity was assessed using the Cochran Q statistic (significance level of P < 0.10) and I2 statistics (significance level of 50%).Results: Ultimately, 18 publications reporting adverse events in CHF patients were included. The results indicate reveal associations between a high level of SUA and the risk of all-cause mortality (HR 2.24, 95% CI 1.49–3.37), cardiovascular mortality (HR 1.14, 95% CI 1.06–1.23), and the composite of death or cardiac events (HR 1.26, 95% CI 1.01–1.56) in CHF patients. A 1 mg/dL increase in serum uric acid led to 4% (HR 1.04, 95% CI 1.02–1.05) and 9% (HR 1.09, 95% CI 1.03–1.17) increases in the risk of all-cause mortality and the composite endpoint of death or cardiac events in CHF patients, respectively.Conclusion: Serum uric acid is positively associated with the risk of adverse events in CHF patients. This study protocol has been registered at PROSPERO as CRD42021247084 (https://www.crd.york.ac.uk/PROSPERO).Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO.

ObjectiveThis systematic review and meta-analysis of prospective cohort studies examined the associations between egg and dietary cholesterol intake and the risk of mortality from all causes, including cardiovascular disease (CVD) and cancer.MethodsWe searched PubMed, Scopus, ISI Web of Knowledge, and Google Scholar until April 2021, as well as references to the relevant articles retrieved. Random-effects models were used to calculate summary relative risk (RR) and 95% confidence intervals (CIs) for the highest vs. lowest categories of egg and dietary cholesterol intake. Also, linear and non-linear dose–response analyses were conducted to examine the dose-response relationships.ResultsWe included 55 studies, comprising data from 2,772,486 individuals with 228,425, 71,745, and 67,211 cases of all-cause, CVD, and cancer mortality, respectively. Intake of each additional egg per day was associated with a 7% higher risk of all-cause (1.07, 95% CI: 1.02–1.12, I2 = 84.8%) and a 13% higher risk of cancer mortality (1.13, 95% CI: 1.06–1.20, I2 = 54.2%), but was not associated with CVD mortality (1.00, 95% CI: 0.92–1.09, I2 = 81.5%). Non-linear analyses showed increased risks for egg consumption of more than 1.5 and 0.5 eggs/day, respectively. Each 100 mg/day increment in dietary cholesterol intake was associated with a 6% higher risk of all-cause mortality (1.06, 95% CI: 1.03–1.08, I2 = 34.5%) and a 6% higher risk of cancer mortality (1.06, 95% CI: 1.05–1.07, I2 = 0%), but was not associated with CVD mortality (1.04, 95% CI: 0.99–1.10, I2 = 85.9%). Non-linear analyses demonstrated elevated risks of CVD and cancer mortality for intakes more than 450 and 250 mg/day, respectively.Conclusions and RelevanceHigh-dietary intake of eggs and cholesterol was associated with all-cause and cancer mortality. Little evidence for elevated risks was seen for intakes below 0.5 egg/day or 250 mg/day of dietary cholesterol. Our findings should be considered with caution because of small risk estimates and moderate between-study heterogeneity.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=252564, PROSPERO, identifier: CRD42021252564.

Background: The association between α-linolenic acid (ALA) and mortality is inconsistent and has not been summarized systematically.Objective: The purpose was to conduct a meta-analysis that synthesized the results of prospective cohort studies to investigate associations between ALA intake and mortality.Methods: We conducted a comprehensive search on PubMed, Embase, and Web of Science databases on May 1, 2021, for relevant prospective cohort studies which reported associations of ALA (assessed by dietary surveys and/or ALA concentrations in body tissues) with mortality from all-cause, cardiovascular disease (CVD), and other diseases. Multivariable-adjusted relative risks (RRs) were pooled by a random or fixed-effects model.Results: A total of 34 prospective cohort studies, of which 17 reported dietary ALA intake, 14 for ALA biomarkers, and the remaining 3 reported both of intake and biomarkers. The studies included 6,58,634 participants, and deaths were classified into all-cause mortality (56,898), CVD mortality (19,123), and other diseases mortality (19,061). Pooled RRs of ALA intake were 0.93 (95% CI: 0.86, 1.01, I2 = 71.2%) for all-cause mortality, 0.90 (95% CI: 0.83, 0.98, I2 = 22.1%) for CVD mortality, and 0.94 (95% CI: 0.83, 1.06, I2 = 73.3%) for other diseases mortality. The two-stage random-effects dose-response analysis showed a linear relationship between dietary ALA intake and CVD-mortality and each 0.5% energy increment of ALA intake was associated with a 5% lower risk of CVD-mortality (RR: 0.95; 95% CI: 0.90, 1.00). Pooled RRs per SD increment of ALA biomarkers were 0.99 (95% CI: 0.96, 1.01, I2 = 27%) for all-cause mortality, 1.00 (95% CI: 0.98, 1.03, I2 = 0%) for CVD mortality and 0.98 (95% CI: 0.95, 1.01, I2 = 0%) for other diseases mortality.Conclusions: This meta-analysis summarizing the available prospective cohort studies indicated that ALA intake was associated with reduced risk of mortality, especially CVD mortality. Our findings suggest that ALA consumption may be beneficial for death prevention. Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO; identifier: CRD42021264532.

Background: The association between α-linolenic acid (ALA) and mortality is inconsistent and has not been summarized systematically.Objective: The purpose was to conduct a meta-analysis that synthesized the results of prospective cohort studies to investigate associations between ALA intake and mortality.Methods: We conducted a comprehensive search on PubMed, Embase, and Web of Science databases on May 1, 2021, for relevant prospective cohort studies which reported associations of ALA (assessed by dietary surveys and/or ALA concentrations in body tissues) with mortality from all-cause, cardiovascular disease (CVD), and other diseases. Multivariable-adjusted relative risks (RRs) were pooled by a random or fixed-effects model.Results: A total of 34 prospective cohort studies, of which 17 reported dietary ALA intake, 14 for ALA biomarkers, and the remaining 3 reported both of intake and biomarkers. The studies included 6,58,634 participants, and deaths were classified into all-cause mortality (56,898), CVD mortality (19,123), and other diseases mortality (19,061). Pooled RRs of ALA intake were 0.93 (95% CI: 0.86, 1.01, I2 = 71.2%) for all-cause mortality, 0.90 (95% CI: 0.83, 0.98, I2 = 22.1%) for CVD mortality, and 0.94 (95% CI: 0.83, 1.06, I2 = 73.3%) for other diseases mortality. The two-stage random-effects dose-response analysis showed a linear relationship between dietary ALA intake and CVD-mortality and each 0.5% energy increment of ALA intake was associated with a 5% lower risk of CVD-mortality (RR: 0.95; 95% CI: 0.90, 1.00). Pooled RRs per SD increment of ALA biomarkers were 0.99 (95% CI: 0.96, 1.01, I2 = 27%) for all-cause mortality, 1.00 (95% CI: 0.98, 1.03, I2 = 0%) for CVD mortality and 0.98 (95% CI: 0.95, 1.01, I2 = 0%) for other diseases mortality.Conclusions: This meta-analysis summarizing the available prospective cohort studies indicated that ALA intake was associated with reduced risk of mortality, especially CVD mortality. Our findings suggest that ALA consumption may be beneficial for death prevention. Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO; identifier: CRD42021264532.

Atorvastatin was the top dispensed chemical drug in England in 2023 with more than 63 million items supplied. This drug is only available via a prescription in the United Kingdom and is used to lower the cholesterol of individuals who suffer from high cholesterol. Thus, reducing the risk of heart attacks and strokes in the process. The third most dispensed drug in this year was levothyroxine sodium which is used to treat those with an underactive thyroid gland, otherwise known as hypothyroidism.

The problem with cholesterol

High cholesterol is classed as having a cholesterol level in the blood supply higher than 5.0 mmol/l. High levels of cholesterol in England are particularly prevalent within people aged 55 and older. In 2018/19, there were approximately 76 percent of women aged 55 to 59 years were classed as living with high cholesterol. The amount of people living with excess levels of cholesterol in England can indicate a reason for Atorvastatin being the most dispensed drug in England.

Dangers of heart disease

As mentioned, another result of high cholesterol is the increased risk of heart disease. Although the number of people diagnosed with coronary heart disease has been fluctuating since 2012. In addition, the mortality rate from heart disease in the UK has been declining since 2000, accounting for 101 deaths per 100,000 population in 2021.

Hypertension, or high-blood pressure, is a condition in which increases a person's chances of suffering from more serious problems such as heart attacks or strokes. In 2022, 34 percent of men and 27 percent of women in England were living with hypertension.